Kings Path Partners »

Biosante Pharmaceuticals shares owned by Kings Path Partners

Quarter-by-quarter ownership of Biosante Pharmaceuticals (ANIP) shares owned by Kings Path Partners from 13F filings

Historical chart of Kings Path Partners investment in Biosante Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Biosante Pharmaceuticals held by Kings Path Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Biosante Pharmaceuticals by Kings Path Partners

Quarter filed Position value Share count Share price at filing
2025-06-30 $657k 10k 65.25
2025-03-31 $798k 12k 66.95
2024-12-31 $1.1M 19k 55.28
2024-09-30 $1.2M 19k 59.66
2024-06-30 $1.0M 16k 63.68

More positions owned by Kings Path Partners

Vanguard Index Fds Total Stk Mkt (VTI)
Schwab Strategic Tr Intl Eqty Etf (SCHF)
Goldman Sachs Etf Tr Activebeta Us Lg (GSLC)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Dimensional Etf Trust Core Fixed Incom (DFCF)
Vanguard Scottsdale Fds Inter Term Treas (VGIT)
Vanguard Scottsdale Fds Short Term Treas (VGSH)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Goldman Sachs Etf Tr Activebeta Int (GSIE)
Dimensional Etf Trust Us Targeted Vlu (DFAT)
American Centy Etf Tr Us Large Cap Vlu (AVLV)
Dimensional Etf Trust Internatnal Val (DFIV)
Dimensional Etf Trust Global Core Plus (DFGP)
Schwab Strategic Tr Us Tips Etf (SCHP)
Vanguard Malvern Fds Core Bd Etf (VCRB)

View all positions for Kings Path Partners

Top funds holding Biosante Pharmaceuticals

BlackRock
Vanguard Group
State Street Corporation
Global Alpha Capital Management
Citadel Advisors
UBS Group
Dimensional Fund Advisors
Geode Capital Management
Deep Track Capital
Point72 Asset Management
Nuveen
Goldman Sachs Group
Arrowstreet Capital, Limited Partnership
William Blair Investment Management
Rubric Capital Management

View all funds holding Biosante Pharmaceuticals